Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer
Therapeutic advances in non-small cell lung cancer (NSCLC) have led to improvements in patient survival, especially in patients who harbor sensitive mutations in the epidermal growth factor receptor (EGFR) gene. Patients with these mutations have exhibited better disease control and prolonged survival when treated with tyrosine kinase inhibitors (TKIs) such as gefitinib [1,2]. However, these improvements in patient survival have been accompanied by an increased incidence of leptomeningeal metastasis (LM) from NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Ya-Lan Wu, Qian Zhao, Lei Deng, Yan Zhang, Xiao-Juan Zhou, Yan-Ying Li, Min Yu, Lin Zhou, Bing-Wen Zou, You Lu, Yong-Mei Liu Source Type: research